Intelligence / Healthtech / New Clinical Trials / Novartis Pharmaceuticals
Clinicaltrial registered22 Oct 2026
Novartis Pharmaceuticals
22 Oct 2026: Trial registered · Managed Access Programs for MAS825, Arumakimig. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 22 Oct 2026
- Title
- Managed Access Programs for MAS825, Arumakimig
- Conditions
- Still's Disease, Including SJIA and AOSD, With MAS or ILD Complications
- Study Type
- Expanded Access
- Status
- Temporarily Not Available
- Reference
- NCT07889310
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Novartis Pharmaceuticals
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Novartis Pharmaceuticals in our registers.
18 NovNovartis Pharmaceuticalstrial registered · HealthtechClinical17 NovNovartis Pharmaceuticalstrial registered · HealthtechClinical16 NovNovartis Pharmaceuticalstrial registered · HealthtechClinical10 NovNovartis Pharmaceuticalstrial registered · HealthtechClinical6 NovNovartis Pharmaceuticalstrial registered · HealthtechClinical6 NovNovartis Pharmaceuticalstrial registered · HealthtechClinical5 NovNovartis Pharmaceuticalstrial registered · HealthtechClinical2 NovNovartis Pharmaceuticalstrial registered · HealthtechClinical2 NovNovartis Pharmaceuticalstrial registered · HealthtechClinical27 OctNovartis Pharmaceuticalstrial registered · HealthtechClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.